Epigenomic profiling of the infrapatellar fat pad in osteoarthritis

Kreitmaier, Peter; Park, Young-Chan; Swift, Diane; Gilly, Arthur; Wilkinson, J Mark; Zeggini, Eleftheria

doi:10.1093/hmg/ddad198

Cited by 7 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When this is known for a locus/pathway, intelligent timing of a pharmacological intervention can then be undertaken, and those which act in later life can be prioritised. Investigations that directly compare multiple joint tissues have also recently proven insightful into the molecular basis of the disease 8,57 . Such studies undertaken throughout the life course will be vital to further elucidate the tissue-specific gene regulatory networks contributing to disease, paving the way for therapeutic intervention.…”

Section: Discussionmentioning

confidence: 99%

Epigenetic mechanisms of osteoarthritis risk in human skeletal development

McDonnell,

Orr,

Barter

et al. 2024

Preprint

View full text Add to dashboard Cite

The epigenome, including the methylation of cytosine bases at CG dinucleotides, is intrinsically linked to transcriptional regulation. The tight regulation of gene expression during skeletal development is essential, with ~1/500 individuals born with skeletal abnormalities. Furthermore, increasing evidence is emerging to link age-associated complex genetic musculoskeletal diseases, including osteoarthritis (OA), to developmental factors including joint shape. Multiple studies have shown a functional role for DNA methylation in the genetic mechanisms of OA risk using articular cartilage samples taken from aged patients. Despite this, our knowledge of temporal changes to the methylome during human cartilage development has been limited. We quantified DNA methylation at ~700,000 individual CpGs across the epigenome of developing human articular cartilage in 72 samples ranging from 7-21 post-conception weeks, a time period that includes cavitation of the developing knee joint. We identified significant changes in 8% of all CpGs, and >9400 developmental differentially methylated regions (dDMRs). The largest hypermethylated dDMRs mapped to transcriptional regulators of early skeletal patterning including MEIS1 and IRX1. Conversely, the largest hypomethylated dDMRs mapped to genes encoding extracellular matrix proteins including SPON2 and TNXB and were enriched in chondrocyte enhancers. Significant correlations were identified between the expression of these genes and methylation within the hypomethylated dDMRs. We further identified 811 CpGs at which significant dimorphism was present between the male and female samples, with the majority (68%) being hypermethylated in female samples. Following imputation, we captured the genotype of these samples at >5 million variants and performed epigenome-wide methylation quantitative trait locus (mQTL) analysis. Colocalization analysis identified 26 loci at which genetic variants exhibited shared impacts upon methylation and OA genetic risk. This included loci which have been previously reported to harbour OA-mQTLs (including GDF5 and ALDH1A2), yet the majority (73%) were novel (including those mapping to CHST3, FGF1 and TEAD1). To our knowledge, this is the first extensive study of DNA methylation across human articular cartilage development. We identify considerable methylomic plasticity within the development of knee cartilage and report active epigenomic mediators of OA risk operating in prenatal joint tissues.

show abstract

Section: Discussionmentioning

confidence: 99%

Epigenetic mechanisms of osteoarthritis risk in human skeletal development

McDonnell,

Orr,

Barter

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Osteoarthritis as an Enhanceropathy: Gene Regulation in Complex Musculoskeletal Disease

Roberts,

Rice

2024

Curr Rheumatol Rep

View full text Add to dashboard Cite

Purpose of Review Osteoarthritis is a complex and highly polygenic disease. Over 100 reported osteoarthritis risk variants fall in non-coding regions of the genome, ostensibly conferring functional effects through the disruption of regulatory elements impacting target gene expression. In this review, we summarise the progress that has advanced our knowledge of gene enhancers both within the field of osteoarthritis and more broadly in complex diseases. Recent Findings Advances in technologies such as ATAC-seq have facilitated our understanding of chromatin states in specific cell types, bolstering the interpretation of GWAS and the identification of effector genes. Their application to osteoarthritis research has revealed enhancers as the principal regulatory element driving disease-associated changes in gene expression. However, tissue-specific effects in gene regulatory mechanisms can contribute added complexity to biological interpretation. Summary Understanding gene enhancers and their altered activity in specific cell and tissue types is the key to unlocking the genetic complexity of osteoarthritis. The use of single-cell technologies in osteoarthritis research is still in its infancy. However, such tools offer great promise in improving our functional interpretation of osteoarthritis GWAS and the identification of druggable targets. Large-scale collaborative efforts will be imperative to understand tissue and cell-type specific molecular mechanisms underlying enhancer function in disease.

show abstract